ProCE Banner Activity

How I Use Immunotherapy to Treat Metastatic HER2-Negative Gastric Cancer

Clinical Thought

In this commentary, Steven Maron, MD, describes how he approaches immunotherapy for treating metastatic, HER2-negative gastric cancer, including a discussion of best practices in managing immune-related adverse events.

Released: November 29, 2022

Expiration: November 28, 2023

Share

Provided by

ProCE Banner

Supporters

This activity is supported by

Bristol Myers Squibb

Additional Information

Program Medium

This program has been made available online.